Novo Nordisk (NVO) Hit with Investor Lawsuit Over CagriSema Obesity Drug - Hagens Berman
Provided By PR Newswire
Last update: Feb 28, 2025
SAN FRANCISCO, Feb. 28, 2025 /PRNewswire/ -- Novo Nordisk A/S (NYSE: NVO) is embroiled in a class-action lawsuit filed by investors who claim they were misled about the future of its experimental obesity treatment, CagriSema.
Read more at prnewswire.com87.17
-0.87 (-0.99%)
Find more stocks in the Stock Screener
NVO Latest News and Analysis
5 days ago - ChartmillInvestors should take note of NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO), a growth stock that remains attractively priced.Uncover the potential of NOVO-NORDISK A/S-SPONS ADR, a growth stock reasonably priced. NYSE:NVO is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive valuation.
